With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Ask an industry onlooker what the following companies have in common – Teva, Viatris, Apotex, Fresenius Kabi, Hikma, Zentiva, Alvotech, Nichi-Iko, Biocon Biologics and Padagis – and they might answer that these firms are among the leading generics and biosimilars players around the world.
While this is accurate, a further characteristic that these firms share is that within the last few months, they have...
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
